RheumNow Week in Review – How Not to Treat Hand OA (8.24.18)
Dr. Jack Cush comments on the last week's news and journal highlights on RheumNow.com.
Dr. Jack Cush comments on the last week's news and journal highlights on RheumNow.com.
A large Canadian study of the drug use in ankylosing spondylitis (AS) demonstrated no evidence that the risk of serious, hospitalized infection was influenced by the use of DMARD and/or of tumour necrosis factor inhibitors (TNFi) therapy.
A study of inpatient systemic sclerosis (SSc) hospitalizations using the 2012–13 National Inpatient Sample database finds an inpatient mortality rate of 5%, and that infection was the most common cause of SSc hospitalizations and in-hospital death.
It has been postulated that TH1 and TH17 pathways are implicated in the pathogenesis of giant cell arteritis (GCA); this is supported by new research showing that interleukin 12 (IL-12) and interleukin 23 (IL-23) may stimulate inflammatory and proliferative pathways relevant to the path
An analysis of Centers for Medicare & Medicaid Services Open Payments Database (OPD) shows a high level of inconsistency for physician self-declared conflicts of interest amongst physicians receiving the highest industry payments.
A systematic review by the Medical Board of the National Psoriasis Foundation examined the role of diet in managing adult patients with psoriasis and/or psoriatic arthritis and suggest that dietary interventions to reduce disease severity.
Reuters reports that the U.S. Health and Human Services Secretary Alex Azar had declared his agency has the authority to eliminate rebates on prescription drug purchases, a key element in the administration’s plan to lower prescription medicine costs.
Yesterday, the American College of Rheumatology (ACR) met with U.S.
Dr. Cush reviews the articles and news from the last week on RheumNow.com. Information on comorbidities, the downside of steroids, unmet need in psoriatic arthritis, and the top 10 rheumatology programs.
Exposure to second-hand smoke during childhood was associated with an increased risk for developing rheumatoid arthritis (RA) later in life, researchers said.
There is a large body of data that shows tumor necrosis factor inhibitors (TNFi) use in rheumatoid arthritis (RA) confers the same risk as that seen in RA - meaning there is no increase over and above that incurred by inflammation and RA itself. There are fewer studies about whether it is s
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.